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LETTERS TO THE EDITORCOMPUTED TOMOGRAPHY
SURVEILLANCE OF PATIENTS
WITH RESECTED LUNG
CANCER: RECURRENCE OR
SECOND PRIMARY LUNG
CANCER?
To the Editor:
We read with interest the results of
the study by Hanna and colleagues1
demonstrating that for survivors of
lung cancer, minimal dose computed
tomography is superior to chest radi-
ography for detecting new or recurrent
lung cancer. Their findings of new or
recurrent lung cancer are consistent
with data from recent work illustrating
that intrathoracic disease progression
represents a high burden in such
patients.2,3 As acknowledged by the
investigators, a limitation of their
study is the lack of distinction
between new and recurrent lung
cancer on follow-up, an important
consideration given the disparate
prognosis associated with each. Pat-
terns of failure studies by Lou and
colleagues2 and Demicheli and col-
leagues3 differentiated between these
2 entities using commonly accepted
criteria,4 and showed that disease de-
tected on follow-up could be attrib-
uted to second primary lung cancer
(SPLC) in 26% and 16% of cases,
respectively.
Specifically in the present study,
the median survival of 25 months
(range, 6-48 months) in asymptom-
atic patients who were referred for
palliative care suggests that some
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The Journalinadvertently been classified as meta-
static disease. We would appreciate it
if the investigators could clarify their
clinical approach for deciding when a
new pulmonary lesion is not an
SPLC, and provide details of the
local therapies used in cases detected
during surveillance, both symptom-
atic (median survival ranging from
7 to 63 months) and asymptomatic.
Was fitness to undergo further
surgery used to decide if invasive re-
staging was mandated? With the
growing availability of stereotactic
ablative radiotherapy, which is a
highly effective local therapy for
high-risk patients, even patients who
are unfit for further surgery may
become eligible for curative therapy
in this situation.5,6
The investigators have provided
useful evidence-based data to support
posttreatment computed tomography
surveillance for early-stage nonsmall
cell lung cancer. Access to these
additional details would be useful for
others who need to implement this in
practice.
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We would like to thank Dr Louie
and Dr Senan for their insightful
comments on our article.1 We
acknowledge that the differentiation
between disease recurrence and a
second primary lung cancer is impor-
tant, but we specifically did not
attempt to make this distinction for
3 reasons. First, unless the 2 tumors
are of different histology, there is
no reliable way of differentiating
them. The criteria suggested by Mar-
tini and Melamed,2 such as tumor
location, intervening lymph node ba-
sins, association with a premalignant
tumor, and DNA ploidy, although
useful, are not absolute. Second,
because lung cancer survivors are at
risk for both recurrence and a second
primary, the distinction may not mat-
ter for the purposes of surveillance.
Third, we believe that new paren-
chymal lesions in lung cancer
survivors should be aggressively
managed and treated, regardless of
whether they are new primary tumors
or isolated local recurrences. Fitness
to undergo a second surgery was
not an absolute criterion for further
invasive investigation, and patients
who were eligible for stereotactic
ablative therapy were evaluated and
treated accordingly. The range of
local therapies used in this study
included further anatomic resection,
nonanatomic resection, external
beam radiation, and stereotacticy c Volume 147, Number 5 1715
Letters to the Editorbody radiation. We are grateful for
the opportunity to discuss these
important issues with you and
look forward to further advances in
the postoperative surveillance and
treatment of lung cancer.
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SCORE ACCURATELY PREDICT
OPERATIVE MORTALITY FOR
PATIENTS WITH PULMONARY
HYPERTENSION?
To the Editor:
We read with interest the article by
Kennedy and colleagues,1 ‘‘Does the
Society of Thoracic Surgeons Risk
Score Accurately Predict Operative
Mortality for Patients With Pulmo-
nary Hypertension?’’ We concur with
Kennedy and colleagues1 that the
current Society of Thoracic Surgeons
system2 poorly models patients with
elevated pulmonary arterial pressure
(PAP) or associated right heart
dysfunction. In our experience and
that of others, patients undergoing car-
diac surgery with PAP hypertension
have worse outcomes than patients
without PAP elevation. An important
question is why is PAP hypertension
an important prognostic marker? To
complement the work by Kennedy
Kennedy and colleagues,1 we would
like to emphasize that although1716 The Journal of Thoracic andelevated PAP is a good marker for
increased morbidity and mortality,
the potential underlying reason for
worse outcomes in these patients is
right heart dysfunction.
For better independent quantifica-
tion of right heart function, we have
begun implementing cardiac magnetic
resonance imaging (cMRI) on a
routine basis for patients deemed to
be at increased risk for right heart
dysfunction arising from elevated
PAP. Use of cMRI allows accurate
interpretation of right ventricular
ejection fraction as well as chamber
volumes or right ventricular end-
diastolic and end-systolic volumes,
which serve as the criterion standard
for establishment of right heart func-
tion in patients with elevated PAP.3
We perform cMRI selectively during
our preoperative workup in patients
with suspected elevated PAP and in
those deemed to be at risk for possible
right heart dysfunction, such as pa-
tients with valvular heart disease and
those with ischemic cardiomy-
opathy.4-6 Patients who are not found
to have any associated right heart
dysfunction are then reevaluated
to establish whether there are
interventions available for medical
optimization, because increased PAP
is often due to other reversible
cardiac causes or noncardiogenic
causes in this subset (sleep apnea,
volume overload, interstitial lung
disease, etc).4 Those who demonstrate
severe right heart dysfunction are also
reevaluated for medical optimization,
as well as for appropriateness of
surgical intervention, especially in
patients with apparent advanced
biventricular disease. Within our
population, this method has allowed
us to improve preoperative risk
stratification and our ability to
select appropriate surgical candidates,
improving our outcomes.5,6
We believe that cMRI should be
used in patients with elevated PAP
(mean PAP >35 mm Hg) to help
define right ventricular function and
better select patients for cardiacCardiovascular Surgery c May 2014surgical procedures. Consideration
should be also given to adding right
heart function to existing risk models
to accurately risk stratify this
population.
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We appreciate the comments by Tra-
chiotis and colleagues on the impor-
tance of right ventricular (RV)
function in perioperative morbidity
and mortality. We agree that a compre-
hensive assessment of RV function
